David Lebovitz
Stock Analyst at Citigroup
(3.35)
# 1,030
Out of 5,122 analysts
91
Total ratings
66.67%
Success rate
10.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Lebovitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $527 → $583 | $397.25 | +46.76% | 33 | Sep 2, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Neutral | $82 → $78 | $58.99 | +32.23% | 4 | May 2, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $378 → $469 | $583.73 | -19.65% | 4 | Feb 27, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Buy | $70 → $74 | $47.39 | +56.15% | 2 | Nov 14, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $37 → $38 | $78.85 | -51.81% | 1 | May 9, 2024 | |
| PTCT PTC Therapeutics | Downgrades: Sell | $29 → $17 | $76.19 | -77.69% | 5 | Oct 27, 2023 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $57 → $54 | $106.76 | -49.42% | 5 | Aug 4, 2021 | |
| IONS Ionis Pharmaceuticals | Maintains: Underweight | $38 → $35 | $78.97 | -55.68% | 6 | May 6, 2021 | |
| MGNX MacroGenics | Maintains: Underweight | $16 → $17 | $1.56 | +989.74% | 11 | Apr 30, 2021 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Equal-Weight | $12 → $11 | $3.33 | +230.33% | 7 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $194 → $199 | $209.34 | -4.94% | 11 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $510 → $480 | $7.31 | +6,466.35% | 2 | Nov 3, 2020 |
Alnylam Pharmaceuticals
Sep 2, 2025
Maintains: Buy
Price Target: $527 → $583
Current: $397.25
Upside: +46.76%
BioMarin Pharmaceutical
May 2, 2025
Maintains: Neutral
Price Target: $82 → $78
Current: $58.99
Upside: +32.23%
Madrigal Pharmaceuticals
Feb 27, 2025
Maintains: Buy
Price Target: $378 → $469
Current: $583.73
Upside: -19.65%
Crinetics Pharmaceuticals
Nov 14, 2024
Maintains: Buy
Price Target: $70 → $74
Current: $47.39
Upside: +56.15%
Mirum Pharmaceuticals
May 9, 2024
Maintains: Buy
Price Target: $37 → $38
Current: $78.85
Upside: -51.81%
PTC Therapeutics
Oct 27, 2023
Downgrades: Sell
Price Target: $29 → $17
Current: $76.19
Upside: -77.69%
Rhythm Pharmaceuticals
Aug 4, 2021
Maintains: Overweight
Price Target: $57 → $54
Current: $106.76
Upside: -49.42%
Ionis Pharmaceuticals
May 6, 2021
Maintains: Underweight
Price Target: $38 → $35
Current: $78.97
Upside: -55.68%
MacroGenics
Apr 30, 2021
Maintains: Underweight
Price Target: $16 → $17
Current: $1.56
Upside: +989.74%
Ironwood Pharmaceuticals
Feb 22, 2021
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $3.33
Upside: +230.33%
Nov 13, 2020
Maintains: Overweight
Price Target: $194 → $199
Current: $209.34
Upside: -4.94%
Nov 3, 2020
Maintains: Overweight
Price Target: $510 → $480
Current: $7.31
Upside: +6,466.35%